On the other hand, several earlier investigations on hematological malignancies reported that CD46 expression was 2–8 folds higher in ALL, AML, CLL and CML patients and in leukemia cell lines compared to normal cells31,32. This evidence concerns the gene CD46 and chronic myelogenous leukemia, BCR-ABL1 positive.